Ilumya (tildrakizumab-asmn) is a prescription medication used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is a human monoclonal antibody that targets the interleukin-23 (IL-23) receptor and works by blocking the action of IL-17A, a cytokine that plays a key role in the development of psoriasis.
However, obtaining access to enrollment forms can be time-consuming and confusing. In this article, we will provide you with access to Ilumya enrollment forms and introduce you to Ilumya support programs – which provide a variety of HCP and patient resources to streamline the process of prescribing.